Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 11, 2003, Pages 1165-1170

  Von Tirpitz, Christian ^a   Epp, Sonja ^a   Klaus, Jochen ^a   Mason, Richard ^a   Hawa, Gerhard ^b   Brinskelle Schmal, Natascha ^b   Hofbauer, Lorenz C ^c   Adler, Guido ^a   Kratzer, Wolfgang ^a   Reinshagen, Max ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Biomedica GmbH   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bone metabolism; Crohn's disease; Osteoprotegerin; Systemic glucocorticoid treatment

Indexed keywords

BIOCHEMICAL MARKER; CYTOKINE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOPROTEGERIN; PREDNISOLONE;

ACUTE DISEASE; ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DENSITOMETRY; DRUG MEGADOSE; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC THERAPY;

ACUTE DISEASE; ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; MALE; OSTEOCALCIN; OSTEOPROTEGERIN; PILOT PROJECTS; PREDNISOLONE; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 10744226443     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200311000-00003     Document Type: Article

References (40)

1. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71-76.
2. Von Tirpitz Ch, Pischulti G, Klaus J, Rieber A, Brueckel J, Boehm BO, et al. Pathologische Knochendichte bei chronisch entzündlichen Darmerkrankungen - Prävalenz und Risikofaktoren. Z Gastroenterol 1999; 37: 5-12.
3. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46:176-181.
4. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133:795-799.
5. Klaus J, Armbrecht G, Steinkamp M, Brueckel J, Rieber A, Adler G, et al. High prevalence of vertebral fractures in patients with Crohn's disease. Gut 2002; 51:654-658.
6. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988; 29:1332-1336.
7. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609-614.
8. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999; 34:696-702.
9. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309:265-268.
10. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986; 45:852-857.
11. Hooyman JR, Melton LJ, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 1984; 27:1353-1361.
12. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328:1747-1752.
13. Sambrook P, Birmingham J, Kempler S, Kelly P, Eberl S, Pocock N, Yeates M. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990; 5:1211-1216.
14. Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996; 81:3441-3447.
15. LoCascio V, Bonnucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990; 8:39-51.
16. Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 1999; 5:200-211.
17. Fucik RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 1975; 40:152-155.
18. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991; 72:382-386.
19. Uebelhart D, Demiaux-Domenech B, Roth M, Chantraine A. Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Paraplegia 1995; 33:669-673.
20. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10:250-256.
21. Stockbrugger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16:1519-1527.
22. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8:87-92.
23. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:268-275.
24. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95:699-704.
25. Pearce G, Tabensky A, Delmas PD, Gordon-Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83:801-806.
26. Hofbauer LC, Heufelder AE. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000; 85:2355-2363.
27. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5:156-160.
28. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JE. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993; 23:95-104.
29. Reid DM, Harvie J. Secondary osteoporosis. Bailliere's Clin Endocrinol Metab 1997; 11:83-99.
30. Cino M, Greenberg GR. Bone mineral density in crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002; 97:915-921.
31. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2002; 119:909-920.
32. MacDonald BR, Gowen M. Cytokines and bone. Br J Rheumatol 1992; 31:149-155.
33. Brändström H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 2001; 280:831-835.
34. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khoshla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140:4382-4389.
35. Vidal NOA, Brändström H, Jonsson KB, Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: downregulation by glucocorticoids. J Endocrinol 1998; 159:191-195.
36. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/ TRANCE/OPGL/ODF gene. Biochem Biophys Acta 1999; 1445: 134-141.
37. Kodaira K, Kodaira K, Mizuno A, Yasuda H, Shima N, Murakami A, et al. Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. Gene 1999; 230:121-127.
38. Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001; 16:479-482.
39. Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin - clinical relevance and potential applications. Eur J Endocrinol 2001; 145:681-683.
40. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-309.